Atlas Trials

Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma

Clinical trial NCT00724568 · COMPLETED

Trial details

NCT number
NCT00724568
Sponsor
University of Michigan Rogel Cancer Center
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2008-05-01
Primary completion
2009-04-01
Enrollment
74

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.